Navigation Links
BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update
Date:2/6/2009

pharmacokinetic (PK) and pharmacodynamic (PD) study. The interim analysis was conducted on data from an exploratory Phase 2 single-arm, open-label program in patients with CLL who failed previous treatment. No partial or complete responses were observed, but five out of 13 patients who were administered 200 mg of Forodesine HCl once-daily had substantial reductions in malignant lymphocytes. Forodesine HCl was generally safe and well-tolerated at the 200 mg once-daily dose. The PK and PD study evaluated the effect of seven days of 200 mg Forodesine HCl dosed either once-daily or twice-daily in healthy volunteers. The study demonstrated substantially increased drug exposure and PD effect in volunteers administered Forodesine HCl 200 mg twice-daily compared to volunteers administered Forodesine HCl 200 mg once-daily. Based on both the CLL interim analysis and the PK and PD study results, the dosing regimen in the ongoing Phase 2 CLL study was amended to evaluate 200 mg Forodesine HCl twice-daily. The Company expects to provide an update on this study by the end of 2009.

BCX-4208

  • A poster entitled, "A Phase 2 Study of the Purine Nucleoside Phosphorylase (PNP) Inhibitor RO5092888 (BCX-4208) in Patients with Moderate to Severe Chronic Plaque Psoriasis: Safety, Tolerability and Lymphocyte Effects" was presented at the 50th American Society of Hematology (ASH) Annual Meeting and Exposition, which was held in San Francisco, December 6-9, 2008. The poster highlighted results from a Phase 2a study that investigated the safety and tolerability of BCX-4208 in patients with moderate to severe chronic plaque psoriasis. Results showed BCX-4208 was safe and well tolerated.

  • BioCryst also presented a poster at ASH entitled, "BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor is a Novel, Potent Orally Active Anti T- and B-Cell Agen
    '/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... NY (PRWEB) , ... August 28, 2015 , ... Since the initial launch of FireflySci ... their quirky humor and excellent customer service. Images such as the Fonz in a ... to add some flavor to the humdrum spectroscopy field. , FireflySci is proud ...
(Date:8/27/2015)... ... ... Capital Edge Consulting , a nationwide consulting firm that specializes in helping ... one of the top 5000 companies listed on the 2015 Inc. 5000 , ... is truly an honor to be recognized as one of America’s fastest growing companies. ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
(Date:8/27/2015)... MENLO PARK, Calif. , Aug. 27, 2015 /PRNewswire/ ... company in the emerging field of regenerative medicine, today ... two investor conferences in the month of September.  ... Officer, will present at Rodman & Renshaw,s 17th Annual ... 10:25am ET/7:25am PT at the St. Regis Hotel in ...
Breaking Biology Technology:Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2
... precisely how fluid boils in tiny "microchannels" has led ... systems to cool high-power electronics in electric and hybrid ... liquid to boil in cooling systems dramatically increases how ... a liquid to below its boiling point, said Suresh ...
... , SAN DIEGO, Sept. 22 SoluLinK, ... the TurboLink Conjugation Catalyst, making conjugation at least 20 times ... peptides and proteins. , , Up to ... conjugation speed for poor yields, poor quality and more labor ...
... , NEW YORK, Sept. 22 ... is available in its catalogue. , , ... and Wireless Systems, Data Processing, EMR Data Transfer) ... , , This report, High-Tech Patient ...
Cached Biology Technology:New findings could help hybrid, electric cars keep their cool 2New findings could help hybrid, electric cars keep their cool 3New findings could help hybrid, electric cars keep their cool 4SoluLinK Introduces Product that Links All Biomolecules Greater Than 20 Times Faster with 100% Yields 2Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report 2Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report 3Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report 4Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report 5Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report 6Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report 7Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report 8Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report 9Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report 10
(Date:7/31/2015)... de 2015 BGI llevará a cabo la 10ª ... al 25 de octubre de 2015, en ... su décimo aniversario este año. Desde su inauguración en ... reuniones anuales más influyentes del mundo en los campos ... científicas más dinámicas, entusiastas y amenas. ICG-10 ...
(Date:7/31/2015)... 2015 La 10 th International Conference on ... BGI del 22 al 25 de octubre de 2015 en ... la conferencia celebra su décimo aniversario. Desde su inauguración en ... las reuniones anuales más influyentes del mundo en el campo ... entusiastas y mejores a nivel científico. ICG-10 ...
(Date:7/31/2015)... -- The 10 th International Conference on Genomics (ICG-10, ... 2015, in Shenzhen , China ... th anniversary this year. Since its inauguration in 2006, ... meetings in the ,omics, fields, and is one of the ... ICG-10 focuses on recent breakthroughs and advances in ,omics, research ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... A. Wells, professor and chairman of the department pharmaceutical ... director of UCSF,s small molecule discovery center, has been ... Biochemistry and Molecular Biology-Merck Award for his pioneering studies ... who also serves on the ASBMB Council, will present ...
... technological innovation with business collaboration to improve conditions for ... new Hunter and Stephanie Hunt Institute for Engineering and ... Gifts totaling $5 million from Hunter and ... B. Lyle and others will establish the institute and ...
... Scientists have designed a synthetic protein that is ... of a native protein, nitric-oxide reductase. , The ... studying nitric-oxide reductase, and for creating biocatalysts for ... Illinois chemistry professor Yi Lu, who directed the ...
Cached Biology News:University of California, San Francisco, researcher receives ASBMB-Merck Award 2New engineering institute to modify, develop technology for the global poor 2New engineering institute to modify, develop technology for the global poor 3Synthetic protein mimics structure, function of metalloprotein in nature 2
solute carrier family 25, member 13 (citrin)...
poliovirus receptor-related 2 (herpesvirus entry mediator B), mRNA...
CREB-2 (H-290)...
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
Biology Products: